Gene · 8205
Papers2,064
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
361 to 380 of 2,064
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Progress in quality control, detection techniques, speciation and risk assessment of heavy metals in marine traditional Chinese medicine. | Chin Med | 2023 | 37328891 | PubTator, text mining | PubMed |
| AXL in cancer: a modulator of drug resistance and therapeutic target. | J Exp Clin Cancer Res | 2023 | 37328828 | PubTator, text mining | PubMed |
| An immune-protein score combining TRAIL, IP-10 and CRP for predicting severe COVID-19 disease. | Cytokine | 2023 | 37327532 | PubTator, text mining | PubMed |
| Tumour-associated macrophages as a potential target to improve natural killer cell-based immunotherapies. | Essays Biochem | 2023 | 37313600 | PubTator, text mining | PubMed |
| Metastatic Breast Cancer: Review of Emerging Nanotherapeutics. | Cancers (Basel) | 2023 | 37296869 | PubTator, text mining | PubMed |
| Stem cells tightly regulate dead cell clearance to maintain tissue fitness. | bioRxiv | 2023 | 37293114 | PubTator, text mining | PubMed |
| A novel copper-induced cell death-related lncRNA prognostic signature associated with immune infiltration and clinical value in gastric cancer. | J Cancer Res Clin Oncol | 2023 | 37291405 | PubTator, text mining | PubMed |
| Barriers to overcoming immunotherapy resistance in glioblastoma. | Front Med (Lausanne) | 2023 | 37275361 | PubTator, text mining | PubMed |
| Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis. | Cancer Chemother Pharmacol | 2023 | 37272931 | PubTator, text mining | PubMed |
| Gas6/AXL pathway: immunological landscape and therapeutic potential. | Front Oncol | 2023 | 37265798 | PubTator, text mining | PubMed |
| Activating the Hippo pathway by nevadensin overcomes Yap-drived resistance to sorafenib in hepatocellular carcinoma. | Discov Oncol | 2023 | 37243813 | PubTator, text mining | PubMed |
| Gas6/Axl Axis Activation Dampens the Inflammatory Response in Osteoarthritic Fibroblast-like Synoviocytes and Synovial Explants. | Pharmaceuticals (Basel) | 2023 | 37242486 | PubTator, text mining | PubMed |
| Hypermucoviscous Carbapenem-Resistant Klebsiella pneumoniae ST25 Infect Human Intestinal Epithelial Cells and Induce Moderate Inflammation. | Int J Mol Sci | 2023 | 37240146 | PubTator, text mining | PubMed |
| PI3K/AKT/mTOR Signaling Pathway in HPV-Driven Head and Neck Carcinogenesis: Therapeutic Implications. | Biology (Basel) | 2023 | 37237486 | PubTator, text mining | PubMed |
| Role and mechanistic actions of protein kinase inhibitors as an effective drug target for cancer and COVID. | Arch Microbiol | 2023 | 37193831 | PubTator, text mining | PubMed |
| Attitudes and associated factors of patients' adoption of patient accessible electronic health records in China - A mixed methods study. | Digit Health | 2023 | 37188077 | PubTator, text mining | PubMed |
| RNF128 expression in lung adenocarcinoma is a favorable prognostic factor associated with decreased tumor-associated macrophages. | Thorac Cancer | 2023 | 37186218 | PubTator, text mining | PubMed |
| Deciphering the involvement of the Hippo pathway co-regulators, YAP/TAZ in invadopodia formation and matrix degradation. | Cell Death Dis | 2023 | 37185904 | PubTator, text mining | PubMed |
| Tumor immune microenvironment (TIME) to enhance antitumor immunity. | Eur J Med Res | 2023 | 37179365 | PubTator, text mining | PubMed |
| Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. | J Exp Clin Cancer Res | 2023 | 37143088 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8205/papers?page=19